BRCA1 MUTATION
Clinical trials for BRCA1 MUTATION explained in plain language.
Never miss a new study
Get alerted when new BRCA1 MUTATION trials appear
Sign up with your email to follow new studies for BRCA1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets cancers with faulty DNA repair
Disease control Recruiting nowThis early-stage trial is testing whether combining two drugs—niraparib and irinotecan—can safely treat advanced solid tumors that have mutations in DNA repair genes like BRCA. The study will enroll 24 adults with various cancers, including breast, ovarian, pancreatic, and others…
Matched conditions: BRCA1 MUTATION
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a combination of two oral drugs, olaparib and ASTX727, in adults with advanced solid tumors that have mutations in genes like BRCA1, BRCA2, PALB2, ATM, or CHEK2. The main goals are to find the safest dose and to check for side effects. About 18 partic…
Matched conditions: BRCA1 MUTATION
Phase: PHASE1 • Sponsor: Varun Monga, MBBS • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New daily pill hopes to control advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…
Matched conditions: BRCA1 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: 858 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental combo aims to overcome drug resistance in metastatic cancers
Disease control Recruiting nowThis early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…
Matched conditions: BRCA1 MUTATION
Phase: PHASE1 • Sponsor: General Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo aims to wipe out prostate tumors before surgery
Disease control Recruiting nowThis phase 2 trial is testing whether giving the targeted drug olaparib (Lynparza) along with hormone therapy for 6 months before surgery can shrink or eliminate prostate cancer in men with high-risk disease and specific gene mutations. About 32 men will receive the treatment, th…
Matched conditions: BRCA1 MUTATION
Phase: PHASE2 • Sponsor: Rana McKay, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for Hard-to-Treat cancers: experimental PARP inhibitor enters human trials
Disease control Recruiting nowThis study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…
Matched conditions: BRCA1 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Acerand Therapeutics (Shanghai) Limited • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New combo therapy aims to slow advanced breast cancer in BRCA patients
Disease control Recruiting nowThis study tests whether adding elacestrant to the standard drug olaparib can help people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a BRCA gene mutation. About 176 participants will be randomly assigned to receive either the combination o…
Matched conditions: BRCA1 MUTATION
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New video aims to ease tough hormone decisions for BRCA patients
Knowledge-focused Recruiting nowThis pilot study tests whether an educational video can help women with BRCA1 or BRCA2 mutations make more informed decisions about hormone replacement therapy after having their ovaries and fallopian tubes removed to lower cancer risk. Fifty premenopausal women scheduled for thi…
Matched conditions: BRCA1 MUTATION
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
10,000 women with BRCA mutations join national study to unlock cancer prevention secrets
Knowledge-focused Recruiting nowThis study is collecting health information from 10,000 women in Italy who carry BRCA1 or BRCA2 gene mutations, which raise the risk of certain cancers. Researchers aim to better understand where these mutations are most common and how to improve care. Participants simply provide…
Matched conditions: BRCA1 MUTATION
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Cancer blood test research launches at princess margaret
Knowledge-focused Recruiting nowThis study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…
Matched conditions: BRCA1 MUTATION
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Can digital tools make cancer genetic counseling more effective?
Knowledge-focused Recruiting nowThis study looks at two new approaches to cancer genetic counseling. The first helps doctors reach out to family members who may have inherited a cancer-related gene change, making it easier for them to get tested. The second uses an online portal to keep patients and their docto…
Matched conditions: BRCA1 MUTATION
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC